Abstract

Poly (ADP-ribose) polymerase-1 (PARP-1) and autophagy play increasingly important roles in DNA damage repair and cell death. Gemcitabine (GEM) remains the first-line chemotherapeutic drug for pancreatic cancer (PC). However, little is known about the relationship between PARP-1 expression and autophagy in response to GEM. Here we demonstrate that GEM induces DNA-damage response and degradation of mono-ADP ribosylated PARP-1 through the autophagy pathway in PC cells, which is rescued by inhibiting autophagy. Hypoxia and serum starvation inhibit autophagic activity due to abrogated GEM-induced mono-ADP-ribosylated PARP-1 degradation. Activation of extracellular regulated protein kinases (ERK) induced by serum starvation shows differences in intracellular localization as well as modulation of autophagy and PARP-1 degradation in GEM-sensitive KLM1 and -resistant KLM1-R cells. Our study has revealed a novel role of autophagy in PARP-1 degradation in response to GEM, and the different impacts of MEK/ERK signaling pathway on autophagy between GEM-sensitive and -resistant PC cells.

Highlights

  • Gemcitabine (GEM) is currently the standard treatment for advanced and metastatic pancreatic cancer (PC) in both adjuvant and palliative settings, but resistance to GEM has been a big problem as its response rate has been reduced to,20% [1,2,3,4]

  • We demonstrated that both light chain 3 (LC3)-I and II were down-regulated in KLM1-R compared to KLM1 cells (Fig. 1 B)

  • Down-regulation of AMP-activated protein kinase A1 (AMPKa1) and unc-51-like kinase 1 (Ulk1) were shown, unlike phosphatidylinositol 3- kinase (PI3K CIII) or Coiled-coil myosin-like BCL2-interacting protein (Beclin-1), in KLM1-R compared to KLM1 cells (Fig. S1 A and B), indicating that the reduction of autophagic activity in GEMresistant KLM1-R cells may be related to the down-regulation of AMPKa1 and/or Ulk1 expression

Read more

Summary

Introduction

Gemcitabine (GEM) is currently the standard treatment for advanced and metastatic pancreatic cancer (PC) in both adjuvant and palliative settings, but resistance to GEM has been a big problem as its response rate has been reduced to ,20% [1,2,3,4]. GEM can inhibit DNA synthesis by targeting ribonucleotide reductase, leading to its inclusion into cellular DNA, causing DNA replication errors [5,6]. Inhibition of checkpoint kinase 1 (Chk1) with chemical inhibitors induced sensitization of PC cells in response to GEM [8,9]. The evidence has shown the relationship between DNA repair and sensitization of cells to GEM, the mechanisms responsible for the repair of GEM-induced DNA damage are not clearly understood

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call